Janus Henderson Group
CYT

Janus Henderson Group’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Janus Henderson Group’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,719,610
Closed -$6.49M – 2716
2022
Q1 		$6.49M Sell
1,719,610
-152,811
-8% -$870K ﹤0.01% 962
2021
Q4 		$20.6M Sell
1,872,421
-5,803
-0.3% -$88.4K 0.01% 779
2021
Q3 		$31.9M Sell
1,878,224
-11,609
-0.6% -$217K 0.01% 675
2021
Q2 		$37.9M Buy
+1,889,833
New +$35.4M 0.02% 639

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group's CYT Position: Q2 2022 in Review

Janus Henderson Group sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 1,719,610 shares — an estimated $6.49M sold.

Janus Henderson Group first reported a position in CYT in Q2 2021 and held it in 4 quarters. The position peaked at $37.9M in Q2 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Janus Henderson Group reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Janus Henderson Group sold 1,719,610 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $6.49M.
  • Janus Henderson Group first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Janus Henderson Group's Cyteir Therapeutics, Inc. Common Stock position peaked at $37.9M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.